The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.
Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based ...
Chief Judge Michael Shea of the federal district court in Connecticut rejected claims that 45 states, the District of Columbia and four U.S. territories waited an unreasonably long time to pursue ...
The top seven customers of the hard-drive company have provided purchase orders through at least the first half of next year. The company said it is on track to meet its advisor retention goals for ...
(Reuters) -Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement ...
Pfizer has filed a lawsuit against Metsera and Novo Nordisk, claiming Metsera violated its merger agreement by entertaining ...
Pfizer has received early U.S. antitrust clearance more than a week early for its proposed $7.3 billion Metsera acquisition, ...
Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more ...
Pfizer said on Friday it has received an early clearance from the U.S. Federal Trade Commission for its proposed acquisition ...
BridgeBio Pharma, Inc.'s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. Learn ...
To our knowledge, this is the greatest survival benefit, based upon hazard ratio, ever seen in a prostate cancer,” said study presenter Stephen J. Freedland, MD.
But Doustdar also seems to recognize what he has in Novo Nordisk, the 100-year-old pharma that brought insulin to the masses, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback